Source: Annual Congress 2011 - Respiratory epidemiology: quality of life, therapy and socioeconomics
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Hoogendoorn, M. Rutten-van Mölken, R. Hoogenveen, M. Al, T. Feenstra (Rotterdam, Bilthoven, Groningen, Netherlands). Comparing the cost-effectiveness of a wide range of COPD interventions using a stochastic population model for COPD. Eur Respir J 2011; 38: Suppl. 55, 4126

Member's Comments

No comment yet.

Related content which might interest you: Prediction models for exacerbations in different COPD patient populations: Results of five large databases Source: International Congress 2016 – COPD and asthma COPD overlap syndrome (ACOS): novelties in terms of prevalence, risk factors, and prognosis in COPD Year: 2016 Evaluating COPD disease management: application of a theoretical model Source: Annual Congress 2008 - Issues in the management of COPD in the community Year: 2008 Real-life COPD patients compared to large trial populations: An UNLOCK external validity study Source: Annual Congress 2013 –Management of respiratory diseases in primary care Year: 2013 Comparison of multidimensional assessment systems with regard to risk prediction for exacerbations of COPD Source: Annual Congress 2011 - COPD exacerbation Year: 2011 Modeling the cost-effectiveness of stratified medicine in COPD Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care Year: 2017 A Markov model based on COPD disease severity to analyse the results from tiotropium trials Source: Eur Respir J 2002; 20: Suppl. 38, 125s Year: 2002 A general framework to implement predictive models for hospitalizations: Application to COPD Source: International Congress 2017 – Best abstracts in the management of chronic respiratory diseases Year: 2017 External validation of exacerbation and mortality outcomes of health economic decision models for COPD Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD Year: 2016 Modelling and simulation in successful drug development programmes: Characterisation of exacerbation reduction with roflumilast to corroborate the importance of defining patient subsets in COPD Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Comparison of five major airflow limitation criteria to identify high-risk individuals with COPD in the general population Source: Virtual Congress 2020 – Prevalence and incidence of chronic lung diseases Year: 2020 Efficiency of different approaches for the assessment of the risk of exacerbations in patients with COPD Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019 Forecasting model for illness behavior types in COPD patients Source: International Congress 2019 – Innovations in care for chronic respiratory conditions Year: 2019 A global survey conducted to determine frequency of exacerbations in COPD patients Source: Annual Congress 2013 –COPD treatment Year: 2013 The effect of different tools in assessing the prevalence of depression in COPD patients Source: Annual Congress 2008 - Quality of life and mood disturbances in rehabilitation Year: 2008 Characteristics of effective self-management interventions in patients with COPD: individual patient data meta-analysis Source: Eur Respir J 2016; 48: 55-68 Year: 2016 Quantifying comorbidity in individuals with COPD: a population study Source: Eur Respir J 2015; 45: 51-59 Year: 2015 Cost and effectiveness of 2 years integrated care intervention in COPD Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Costs of COPD exacerbations in a general population. Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Comparison of COPD patients with high and low symptoms from a real-world US survey Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases Year: 2015 COPD severity and health impact across the current CanCOLD population Source: Annual Congress 2012 - COPD: epidemiology and varia Year: 2012